Side Effect Profile of Arimidex vs. Femara: A Comparison Study Side Effects of Arimidex vs. Femara
Article Sidebar
Main Article Content
Abstract
Background: Background: Aromatase inhibitors, Arimidex (anastrozole) and Femara (letrozole), are commonly used in the treatment of hormone receptor-positive (HR+) breast cancer in postmenopausal women. Despite similar efficacy, these drugs have different side effect profiles that impact patient compliance and quality of life.
Objective: To compare the incidence and severity of side effects between Arimidex and Femara in postmenopausal women with HR+ breast cancer.
Methods: A retrospective cohort study was conducted involving 1,000 postmenopausal women with HR+ breast cancer from multiple oncology centers. Participants were divided into two groups: Arimidex (n=500) and Femara (n=500). Side effects were assessed via patient self-reports, clinical evaluations, and standardized questionnaires. Data were analyzed using chi-square tests, t-tests, and logistic regression models, with p-values <0.05 considered significant.
Results: Arimidex was associated with higher rates of joint pain (45% vs. 30%, p<0.001) and muscle pain (38% vs. 25%, p<0.01). Femara showed increased rates of hypertension (28% vs. 20%, p<0.05) and significant bone density loss (18% vs. 12%, p<0.05).
Conclusion: Arimidex and Femara exhibit distinct side effect profiles, suggesting the need for personalized treatment approaches based on patient risk factors.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Bell SG. Aromatase Inhibitor Use, Side Effects and Discontinuation Rates in Gynecologic Oncology Patients. Gynecologic Oncology. 2020;159(2):509-514.
Zhao F. Toxicity of Extended Adjuvant Endocrine Therapy with Aromatase Inhibitors in Patients with Postmenopausal Breast Cancer: A Systematic Review and Meta-Analysis. Critical Reviews in Oncology/Hematology. 2020;156:103114.
Robertson JF. Meta-Analyses of Phase 3 Randomised Controlled Trials of Third Generation Aromatase Inhibitors Versus Tamoxifen as First-Line Endocrine Therapy in Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer. European Journal of Cancer. 2021;145:19-28.
Peddie N. The Impact of Medication Side Effects on Adherence and Persistence to Hormone Therapy in Breast Cancer Survivors: A Qualitative Systematic Review and Thematic Synthesis. The Breast. 2021;58:147-159.
Cucciniello L. Estrogen Deprivation Effects of Endocrine Therapy in Breast Cancer Patients: Incidence, Management and Outcome. Cancer Treatment Reviews. 2023;120:102624.
Aggarwal S. Drug Repurposing for Breast Cancer Therapy: Old Weapon for New Battle. Seminars in Cancer Biology. 2021;68:8-20.
Cucciniello L. Tailoring Adjuvant Endocrine Therapy in Early Breast Cancer: When, How, and How Long? Cancer Treatment Reviews. 2022;110:102445.
Malik JA. Drugs Repurposed: An Advanced Step Towards the Treatment of Breast Cancer and Associated Challenges. Biomedicine & Pharmacotherapy. 2022;145:112375.
Moscetti L. Quality of Life of Therapies for Hormone Receptor Positive Advanced/Metastatic Breast Cancer: Regulatory Aspects and Clinical Impact in Europe. The Breast. 2021;59:232-238.
Fasching PA. Prognostic Impact of Selection Criteria of Current Adjuvant Endocrine Therapy Trials NATALEE and MonarchE in Postmenopausal HRpos/HER2neg Breast Cancer Patients Treated with Upfront Letrozole. European Journal of Cancer. 2024;209:114239.
Yang L. The Effect of Exemestane Administration on the Lipid Profile in Women: Meta-Analysis of Randomized Controlled Trials. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2024;295:25-33.
Rochoy M. Doping with Aromatase Inhibitors and Oestrogen Receptor Modulators in Steroid Users: Analysis of a Forum to Identify Dosages, Durations and Adverse Drug Reactions. Therapies. 2022;77(6):683-691.
W. MB EM. Management of Hormone Receptor-Positive, HER2-Negative Early Breast Cancer. Seminars in Oncology. 2020;47(4):187-200.
Hasson SP. Adjuvant Endocrine Therapy in HER2-Positive Breast Cancer Patients: Systematic Review and Meta-Analysis. ESMO Open. 2021;6(2):100088.
Taheri H. Quantification of the Aromatase Inhibitor Letrozole and Its Carbinol Metabolite in Mouse Plasma by UHPLC-MS/MS. Journal of Chromatography B. 2024;1238:124106.
Bhatia N. Selective Estrogen Receptor Degraders (SERDs) for the Treatment of Breast Cancer: An Overview. European Journal of Medicinal Chemistry. 2023;256:115422.
McAndrew NP. Management of ER Positive Metastatic Breast Cancer. Seminars in Oncology. 2020;47(5):270-277.
P BSc CL. Effect of Traditional Chinese Medicine on Musculoskeletal Symptoms in Breast Cancer: A Systematic Review and Meta-Analysis. Journal of Pain and Symptom Management. 2021;62(1):159-173.
Battisti NML. Systemic Therapy for Older Patients with Early Breast Cancer. Cancer Treatment Reviews. 2021;100:102292.
Khan J. Exploring Triazole-Based Drugs: Synthesis, Application, FDA Approvals, and Clinical Trial Updates – A Comprehensive Review. Tetrahedron. 2024;162:134122.
Rani S. A Review on Diverse Heterocyclic Compounds as the Privileged Scaffolds in Non-Steroidal Aromatase Inhibitors. Bioorganic Chemistry. 2021;113:105017.
Meattini I. Omission of Radiation Therapy After Breast-Conserving Surgery for Biologically Favourable Tumours in Younger Patients: The Wrong Answer to the Right Question. Radiotherapy and Oncology. 2024;190:110045.